Long-term renal survival in malignant hypertension

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3266-3272

  González, Roberto ^a   Morales, Enrique ^a   Segura, Julian ^a   Ruilope, Luis M ^a   Praga, Manuel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

malignant hypertension; proteinuria; RAS blockade; renal survival

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; INCIDENCE; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES;

EID: 77957241014     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq143     Document Type: Article

References (21)

1. Herlitz H, Thorkell G, Hansson L. Renal function as an indicator of prognosis in malignant essential hypertension. Scand J Urol Nephrol 1982; 16: 51-55
2. Scarpelli PT, Gallo M, De Cesaris F et al. Continuing follow-up of malignant hypertension. J Nephrol 2002; 15: 431-437
3. Edmunds E, Beevers DG, Lip GYH. What has happened to malignant hypertension? A disease no longer vanishing. J Hum Hypertens 2000; 14: 159-161
4. Lip GYH, Beevers M, Beevers DG. The failure of malignant hypertension to decline: a survey of 24 years' experience. J Hypertens 1994; 12: 1297-1305
5. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332-343
6. Leishman AWD. Hypertension: treated and untreated, a study of 400 cases. BMJ 1959; 1: 1361-1363
7. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilledema malignant hypertension. QJM 1958; 27: 117-152
8. Gudbrandsson T, Hansson L, Herlitz H, Andreu L. Malignant hypertension\improving prognosis in a rare disease. Acta Med Scand 1979; 206: 495-499
9. Isles CG, Lim KG, Boulton-Jones M et al. Factors influencing mortality in malignant hypertension. J Hypertens 1985; 3: S405-S407
10. Rivera F, Samper P, Daniel A, González C, Giménez E, Olivares J. Malignant hypertension. Study of 86 cases. Nefrología 1986; 6: 69-80
11. Lip GYH, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13: 915-924
12. Martínez-Amenós J, Carratalá J, Pintó X. Malignant arterial hypertension. Clinical aspects and prognostic factors in 165 cases (1974-1984). Med Clin 1987; 88: 661-665
13. Van Den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 2006; 24: 2299-2304
14. James SH, Meyers AM, Milne FJ, Reinach SG. Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension. Nephron 1995; 71: 29-34
15. Yu SH, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: aetiology and outcome in 83 patients. Clin Exp Hypertens 1986; 8: 1211-1230
16. Lip G, Beevers M, Beevers G. Does renal function improve after diagnosis of malignant phase hypertension? J Hypertens 1997; 15: 1309-1315
17. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseases. Kidney Int 2001; 60: 1131-1140
18. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546
19. Textor SC, Canzanello VJ. Importance of blood pressure reduction for prevention of progression of renal disease. Curr Hypertens Rep 2009; 1: 423-430
20. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
21. Montgomery HE, Kiernan LA, Whitworth CE et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998; 16: 635-643